Japanese drugmaker plans to cut debt by half in 3-5 years to keep credit rating
Welcome to our new website
As well as being able to load content faster than ever before, you'll now find it's much easier to find all the content you need about the Asian business world.
Positive Wall Street cues also add to momentum
Expiring patents on mainstay treatments pose a challenge for new boss
Japanese drugmaker now has until May 8 to firm up record $64bn deal
Hindalco, National Aluminium plunge